Alternative splicing-based therapeutics for neurodegenerative diseases: a dual-database bibliometric and NLP-driven analysis (2000–2025) - Summary - MDSpire

Alternative splicing-based therapeutics for neurodegenerative diseases: a dual-database bibliometric and NLP-driven analysis (2000–2025)

  • By

  • De-Zhu Liu

  • Gao-Lu Cheng

  • Chen-Feng Hu

  • Ru-Yang Li

  • Cong-Chu Yang

  • Ning-Chuan Chen

  • Xiang Li

  • De-You Jiang

  • Jia-Yi Chang

  • June 16, 2026

  • 0 min

Share

Objective:

To systematically analyze global research trends, conceptual frameworks, and clinical evolution of alternative splicing (AS)-based therapeutics for neurodegenerative diseases (NDDs), highlighting their significance in addressing therapeutic gaps.

Approach:
    Key Findings:
    • Sustained linear growth in publication output from 2000 to 2025, indicating increasing interest in AS-based therapeutics.
    • The United States and Western Europe are dominant collaborative hubs, while China shows high productivity but limited international integration, suggesting potential for enhanced global collaboration.
    • LDA topic modeling identified three core conceptual axes: molecular mechanisms, disease-specific pathological models, and translational methodological frameworks, which are crucial for guiding future research.
    • Keyword trajectories indicate a shift from in vitro exploration to clinical drug discovery and RNA therapeutics, reflecting the evolving landscape of NDD treatment.
    • CLARA clustering revealed a concentration of splicing-modifying interventions in pediatric spinal muscular atrophy (SMA), highlighting the need for similar approaches in adult NDDs.
    Interpretation:

    The study delineates the structural landscape of AS-based therapeutics for NDDs, indicating a shift from descriptive molecular biology to clinically actionable splicing interventions, which could significantly impact treatment strategies.

    Limitations:
    • The analysis is limited to publications available in the selected databases (WoSCC and PubMed), which may not encompass all relevant research.
    • The study may not capture all relevant research trends outside the specified timeframe, potentially overlooking emerging studies.
    Conclusion:

    Insights from this study highlight the need to expand targeted RNA platforms beyond SMA into adult neurodegenerative populations, providing a roadmap for future translational research and emphasizing the urgency of addressing adult NDDs.

Original Source(s)

Related Content